Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Wildemore, JK; Schuchter, L; Mick, R; Synnestvedt, M; Elenitsas, R; Bedrosian, I; Czerniecki, BJ; Guerry, D; Lessin, SR; Elder, DE; Bucky, LP
   Locally recurrent malignant melanoma characteristics and outcomes: A single-institution study
   ANNALS OF PLASTIC SURGERY
   
   J.K. Wildemore et al., "Locally recurrent malignant melanoma characteristics and outcomes: A single-institution study", ANN PL SURG, 46(5), 2001, pp. 488-494
2. Chang, JH; Vines, E; Bertsch, H; Fraker, DL; Czerniecki, BJ; Rosato, EF; Lawton, T; Conant, EF; Orel, SG; Schuchter, L; Fox, KR; Zieber, N; Glick, JH; Solin, LJ
   The impact of a multidisciplinary breast cancer center on recommendations for patient management - The University of Pennsylvania experience
   CANCER
   
   J.H. Chang et al., "The impact of a multidisciplinary breast cancer center on recommendations for patient management - The University of Pennsylvania experience", CANCER, 91(7), 2001, pp. 1231-1237
3. Visonneau, S; Cesano, A; Porter, DL; Luger, SL; Schuchter, L; Kamoun, M; Torosian, MH; Duffy, K; Sickles, C; Stadtmauer, EA; Santoli, D
   Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer
   CLINICAL CANCER RESEARCH
   
   S. Visonneau et al., "Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer", CLIN CANC R, 6(5), 2000, pp. 1744-1754
4. Bedrosian, I; Faries, MB; Guerry, D; Elenitsas, R; Schuchter, L; Mick, R; Spitz, FR; Bucky, LP; Alavi, A; Elder, DE; Fraker, DL; Czerniecki, BJ
   Incidence of sentinel node metastasis in patients with thin primary melanoma (<= 1 mm) with vertical growth phase
   ANNALS OF SURGICAL ONCOLOGY
   
   I. Bedrosian et al., "Incidence of sentinel node metastasis in patients with thin primary melanoma (<= 1 mm) with vertical growth phase", ANN SURG O, 7(4), 2000, pp. 262-267
5. Shaw, LM; Bonner, HS; Schuchter, L; Schiller, J; Lieberman, R
   Pharmacokinetics of amifostine: Effects of dose and method of administration
   SEMINARS IN ONCOLOGY
   
   L.M. Shaw et al., "Pharmacokinetics of amifostine: Effects of dose and method of administration", SEMIN ONCOL, 26(2), 1999, pp. 34-36
6. DiPaola, RS; Schuchter, L
   Neurologic protection by amifostine
   SEMINARS IN ONCOLOGY
   
   R.S. DiPaola e L. Schuchter, "Neurologic protection by amifostine", SEMIN ONCOL, 26(2), 1999, pp. 82-88
7. Van Belle, PA; Elenitsas, R; Satyamoorthy, K; Wolfe, JT; Guerry, D; Schuchter, L; Van Belle, TJ; Albelda, S; Tahin, P; Herlyn, M; Elder, DE
   Progression-related expression of beta 3 integrin in melanomas and nevi
   HUMAN PATHOLOGY
   
   P.A. Van Belle et al., "Progression-related expression of beta 3 integrin in melanomas and nevi", HUMAN PATH, 30(5), 1999, pp. 562-567
8. Alpaugh, RK; von Mehren, M; Palazzo, I; Atkins, MB; Sparano, JA; Schuchter, L; Weiner, LM; Dutcher, JP
   Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon
   MEDICAL ONCOLOGY
   
   R.K. Alpaugh et al., "Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/alpha-interferon", MED ONCOL, 15(3), 1998, pp. 191-198
9. Margolis, DJ; Halpern, AC; Rebbeck, T; Schuchter, L; Barnhill, RL; Fine, J; Berwick, M
   Validation of a melanoma prognostic model
   ARCHIVES OF DERMATOLOGY
   
   D.J. Margolis et al., "Validation of a melanoma prognostic model", ARCH DERMAT, 134(12), 1998, pp. 1597-1601
10. GRECO FA; FIGLIN R; YORK M; EINHORN L; SCHILSKY R; MARSHALL EM; BUYS SS; FROIMTCHUK MJ; SCHULLER J; SCHUCHTER L; BUYSE M; RITTER L; MAN A; YAP AKL
    PHASE-III RANDOMIZED STUDY TO COMPARE INTERFERON ALFA-2A IN COMBINATION WITH FLUOROURACIL VERSUS FLUOROURACIL ALONE IN PATIENTS WITH ADVANCED COLORECTAL-CANCER
    Journal of clinical oncology
    
    F.A. Greco et al., "PHASE-III RANDOMIZED STUDY TO COMPARE INTERFERON ALFA-2A IN COMBINATION WITH FLUOROURACIL VERSUS FLUOROURACIL ALONE IN PATIENTS WITH ADVANCED COLORECTAL-CANCER", Journal of clinical oncology, 14(10), 1996, pp. 2674-2681
11. SCHUCHTER L; SCHULTZ DJ; SYNNESTVEDT M; TROCK BJ; GUERRY D; ELDER DE; ELENITSAS R; CLARK WH; HALPERN AC
    A PROGNOSTIC MODEL FOR PREDICTING 10-YEAR SURVIVAL IN PATIENTS WITH PRIMARY MELANOMA
    Annals of internal medicine
    
    L. Schuchter et al., "A PROGNOSTIC MODEL FOR PREDICTING 10-YEAR SURVIVAL IN PATIENTS WITH PRIMARY MELANOMA", Annals of internal medicine, 125(5), 1996, pp. 369-375
12. SCHUCHTER L; DIPAOLA R; GREENBERG R; BIRD S; MOLLMAN J; RECIO A; LIST A; TAYLOR C; ALBERTS D
    A PHASE-I STUDY OF AMIFOSTINE (AMI) AND ESCALATING DOSES OF TAXOL IN PATIENTS (PTS) WITH ADVANCED CANCER
    European journal of cancer
    
    L. Schuchter et al., "A PHASE-I STUDY OF AMIFOSTINE (AMI) AND ESCALATING DOSES OF TAXOL IN PATIENTS (PTS) WITH ADVANCED CANCER", European journal of cancer, 31A, 1995, pp. 958-958
13. NAKASHIMA M; JANISZEWSKA M; STEPLEWSKI Z; WATANABE T; SCHUCHTER L; KOPROWSKI H
    PROLIFERATION, PHENOTYPE, AND CYTOTOXICITY OF HUMAN-LYMPHOCYTES ISOLATED FROM LYMPH-NODES INVADED BY MELANOMA-CELLS
    Hybridoma
    
    M. Nakashima et al., "PROLIFERATION, PHENOTYPE, AND CYTOTOXICITY OF HUMAN-LYMPHOCYTES ISOLATED FROM LYMPH-NODES INVADED BY MELANOMA-CELLS", Hybridoma, 13(3), 1994, pp. 241-246
14. NAKASHIMA M; WATANABE T; KOPROWSKI H; SCHUCHTER L; STEPLEWSKI Z
    IN-VITRO EXPANSION OF TUMOR-SPECIFIC, HLA-RESTRICTED HUMAN CD8(-LYMPHOCYTES() CYTOLYTIC T)
    Cellular immunology
    
    M. Nakashima et al., "IN-VITRO EXPANSION OF TUMOR-SPECIFIC, HLA-RESTRICTED HUMAN CD8(-LYMPHOCYTES() CYTOLYTIC T)", Cellular immunology, 155(1), 1994, pp. 53-61